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Lung cancer is the leading cause of cancer death, and ﬁve-year survival remains poor, raising the urgency for new treatment
strategies. Activation of PPARγ represents a potential target for both the treatment and prevention of lung cancer. Numerous
studies have examined the eﬀect of thiazolidinediones such as rosiglitazone and pioglitazone on lung cancer cells in vitro and in
xenograft models. These studies indicate that activation of PPARγ inhibits cancer cell proliferation as well as invasiveness and
metastasis. While activation of PPARγ can occur by direct binding of pharmacological ligands to the molecule, emerging data
indicate that PPARγ activation can occur through engagement of other signal transduction pathways, including Wnt signaling and
prostaglandin production. Data, both from preclinical models and retrospective clinical studies, indicate that activation of PPARγ
may represent an attractive chemopreventive strategy. This article reviews the existing biological and mechanistic experiments
focusing on the role of PPARγ in lung cancer, focusing speciﬁcally on nonsmall cell lung cancer.
Copyright © 2008 Raphael A. Nemenoﬀ et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Lung cancer is the leading cause of cancer death for both
men and women in the USA. In fact, more deaths will
occur this year due to lung cancer than breast, prostate,
and colorectal cancers combined [1]. In spite of intensive
research,5-yearsurvivalinpatientswithlungcancerremains
dismallylow,withoverallsurvivalat15%[2].Amajorreason
for this problem is the presence of metastasis at the time
of diagnosis. While smoking cessation will clearly reduce
the risk of lung cancer, a majority of diagnosed cases are
being detected in exsmokers [3]. Therefore, in addition to
new chemotherapeutic approaches, there appears to be a
critical need for chemopreventive strategies which can be
administered to patients at risk for developing lung cancer.
In this article, we will review recent data, both from basic
sciencesexperimentsandfromclinicalstudiesindicatingthat
activation of the nuclear receptor peroxisome proliferator-
activated receptor γ (PPARγ)m a yr e p r e s e n tan o v e ls t r a t e g y
for the treatment and prevention of lung cancer.
2. BIOLOGY OF LUNG CANCER
Lung cancers are categorized as small cell lung cancer
(SCLC) and nonsmall cell lung cancer (NSCLC). As a
group, the NSCLC constitute the bulk of lung cancers and
are subdivided into squamous, adenocarcinoma, and large
cell carcinoma phenotypes. Selective changes in speciﬁc
oncogenes can be used to distinguish the two types of
cancer. Activating mutations in ras are associated with
NSCLC, with a mutation at codon 12 of the Ki-Ras gene
observed in approximately 30% of adenocarcinomas, and
just under 10% of other NSCLC types [4]. These mutations
appear to be virtually absent from SCLC [5]. In mice, Ki-
ras mutations are found in over 90% of spontaneous and
chemicallyinducedlungtumors[6].Overexpressionofthec-
myc gene is also frequently observed in NSCLC, but appears
to be more prevalent in SCLC [7]. Elevated expression of
the HER-2/neu gene, a member of the epidermal growth
factor receptor family has also been observed in 35%
of adenocarcinomas and a slightly lower percentage of2 PPAR Research
squamous carcinomas [8]. Alterations in tumor suppressor
genes have also been reported. Mutations in p53 have been
detected in 90% of SCLC and 50% of NSCLC [7]. Mutations
in the retinoblastoma gene are more speciﬁc for SCLC,
occurring in more than 90%, while only a small fraction
of NSCLC have mutations in this gene. Recently, mRNA
expression proﬁling has been used to deﬁne subclasses of
lung adenocarcinoma, which can be deﬁned by distinct
patternsofgeneexpression[9,10].Thesestudiessuggestthat
NSCLC may in fact represent multiple diseases characterized
by distinct molecular pathways. In contrast to most NSCLC,
SCLC displays neuroendocrine features exempliﬁed by the
presence of cytoplasmic neurosecretory granules contain-
ing a wide variety of mitogenic neuropeptides including
gastrin-releasing peptide, arginine vasopressin, neurotensin,
cholecystokinin, and many others [11, 12]. Signiﬁcantly,
SCLC also expresses G protein-coupled receptors (GPCR)
for these neuropeptides, thereby establishing autocrine-
stimulated cell growth. Therapeutic strategies have targeted
these neuropeptides using inhibitors of GPCRs. However,
the existence of potentially redundant loops mediated by
multiple neuropeptides has limited the usefulness of this
strategy.
Recently, a great deal of attention has been focused on
the EGF receptor, and the use of selective inhibitors of
the EGF receptor tyrosine kinase (EGFR-TKI). These agents
(geﬁtinib and erlotinib) have shown therapeutic eﬃcacy in
a subset of NSCLC patients which have somatic mutations
in this receptor [13, 14]. However, responses have also
been observed in patients with wild-type EGFR. Identifying
strategies which would sensitize patients to EGFR-TKI
therapy is under active investigation (see [15] for review).
3. PPARγ ACTIVATION
PPARγ is a member of nuclear receptor superfamily. Two
m a j o ri s o f o r m sh a v eb e e nd e s c r i b e d ,P P A R γ1a n dP P A R γ2
(see [16] for review). These are splice variants, with PPARγ2
being expressed predominantly in adipose tissue, whereas
PPARγ1hasamorewidespreaddistribution,andisexpressed
in cancer cells, including lung cancer [16]. More recently
a number of additional splice variants have been identiﬁed
[17]. The role of these forms of PPARγ remains to be
established. The structure of PPARγ is similar to that of
most nuclear receptors; the core of the molecule consists
of a DNA-binding region (DBD) and a ligand-binding
region (LBD), separated by a hinge region. There are two
activation domains, AF-1 at the amino terminal and AF-
2 at the carboxyl terminal. The classic pathway of PPARγ
activationinvolvesbindingasaheterodimerwiththeretinoic
acid X receptor to speciﬁc DNA sequences (PPAR-RE).
The consensus PPAR site consists of a direct repeat of
the sequence AGGTCA, separated by a single nucleotide,
designated a DR-1 site. Ligand binding to the LBD causes
a conformational change, which results in the release of
corepressors and the binding of coactivators, resulting in
increased transcription of target genes.
PPARγ is activated by polyunsaturated fatty acids and
eicosanoids. In particular, 15-deoxy-Δ12,14-PGJ2(dPGJ2)h a s
been shown to speciﬁcally activate PPARγ with micromolar
aﬃnity [18]. Lipoxygenase products of linoleic acid, 9- and
13-HODE have micromolar aﬃnities for PPARγ [19]. It is
not clear whether any of these agents are actual physiologic
regulators of PPARγ, and a recent study has found that
endogenous levels of dPGJ2 do not change during adipocyte
diﬀerentiation [20]. Synthetic activators of PPARγ include
thethiazolidinediones,suchasrosiglitazoneandpioglitazone
[21]. These compounds have insulin-sensitizing and antidia-
beticactivity,whichislikelymediatedatleastinpartthrough
PPARγ activation. Finally, NSAIDs, which inhibit eicosanoid
production, activate PPARγ albeit at higher concentrations
than required for COX inhibition [22]. While all of these
agents can activate PPARγ, it is clear that they also stimulate
“oﬀ-target” pathways which may impact their therapeutic
potency [23]. Finally, it should be noted that PPARγ can
directly bind to other transcription factors, including NF-
κBa n dS p 1[ 24]. This mechanism of action complicates
the spectrum of genes that could be regulated by PPARγ by
engaging regulatory elements distinct from classic PPAR-RE
sites [25].
4. CLINICAL ASSOCIATIONS WITH
PPARγ IN LUNG CANCER
Analysis of human lung tumors has reported that decreased
expression of PPARγ is correlated with a poor prognosis
[26]. Further work indicated that expression of PPARγ as
detected by immunohistochemistry was more frequently
detected in well-diﬀerentiated adenocarcinomas, compared
to poorly diﬀerentiated ones. Recently, a retrospective study
demonstrated a 33% reduction in lung cancer risk in
diabetic patients using the TZD rosiglitazone [27]. An even
more dramatic reduction was observed in African-American
patients (75%). This decreased risk appeared to be speciﬁc
for lung cancer, and no protective eﬀect was observed for
prostate or colon cancer. Genetic variants in the PPARγ
gene have been identiﬁed which are associated with a
decreased risk for lung cancer [28]. These ﬁndings suggest
that chemoprevention strategies using PPARγ activators may
be an attractive approach in patients at risk for lung cancer,
and that polymorphisms in the PPARγ gene may be a way
to screen those patients. There are several chemoprevention
trials being initiated using TZDs. However, a concern in
these studies is the association of higher rates of adverse
cardiac events with chronic TZD treatment, especially with
rosiglitazone [29]. As discussed below, agents which target
PPARγ throughalternativepathwaysmaythereforerepresent
novel therapeutic targets.
5. BIOLOGICAL EFFECTS OF PPARγ IN
LUNG CANCER CELLS
A number of studies have examined the eﬀects of TZDs on
the growth of lung cancer cells. The majority of these studies
have focused on NSCLC. Administration of TZDs has been
shown to inhibit growth and induce apoptosis in numerous
NSCLC cell lines [30–34]. While the mechanisms for these
eﬀects are not completely understood, they appear to beRaphael A. Nemenoﬀ et al. 3
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Figure 1: Activation pathways for PPARγ.P P A R γ forms a heterodimer with the retinoic acid X receptor (RXR). Activation can occur by
thiazolidinidiones (TZD)suchasrosiglitazoneor pioglitazone directlybindingtotheligand-bindingdomain.Thisresultsinthedissociation
of corepressors such as NCor and SMRT, and the binding of coactivators such as p300 and Src, mediating activation of transcription. In lung
cancer cells, binding of Wnt7a to its cognate receptor Fzd9 leads to activation of ERK5, which presumably directly binds to the hinge region
ofPPARγ mediatingactivation.Prostacyclin(PGI)andanalogssuchasiloprostcanalsoleadtoPPARγ activation,andthismayinvolveERK5
activation. Conversely, activation of the ERK or JNK family of MAP kinases can inhibit PPARγ activation; this is mediated through direct
phosphorylation of the molecule which alters the ligand binding aﬃnity. Finally, activation of PPARγ/RXR heterodimers may be activated
through retinoic acid (RA) binding to RXR.
mediated through both PPARγ-dependent and independent
eﬀects. Induction of apoptosis may involve the tumor
necrosis factor-related apoptosis-inducing ligand (TRAIL)-
induced apoptosis in some cancer cell lines [35]; these
eﬀects appear to be mediated through PPARγ-independent
pathways.Recentstudies havealsodemonstrated thatPPARγ
activation induces proline oxidase, which will result in
increased production of cytotoxic reactive oxygen species
(ROS) [36]. Growth arrest may be mediated through
induction of the cyclin kinase inhibitor p21 [37]. In this
case, the mechanism of action involves PPARγ-dependent
induction of p21 through interactions with other transcrip-
tion factors. Several studies, including work from our own
laboratoryhavedemonstratedthatactivationofPPARγ leads
to promotion of a more highly diﬀerentiated phenotype in
NSCLC [32, 38]. This can be assessed by growing cells in 3-
dimensional tissue culture, which has been shown to reveal
epithelial features. E-cadherin is perhaps to most widely
studied marker of epithelial diﬀerentiation, and both phar-
macological PPARγ activators and molecular overexpression
of PPARγ had shown increased protein and mRNA for E-
cadherin. Epithelial mesenchymaltransition hasbeen associ-
ated with cancer progression and metastasis [39]. While this
is still somewhat of a controversial area [40], activation of
PPARγ in lung cancer cells appears to inhibit invasiveness, at
least in part through inhibiting or reversing EMT.
It has become evident during the past several years,
that while genetic changes in cancer cells are critical
for tumor initiation, progression and metastasis entail a
critical contribution from the tumor microenvironment
[41]. Speciﬁcally, interactions of tumor cells with vascular
cells, innate immune cells, and ﬁbroblasts control tumor
angiogenesis and promote a more aggressive phenotype.
These cell-cell interactions are mediated through cytokines
and growth factors initially produced by the tumor cells
which recruit stromal cells. Among these cytokines are
factors such as MCP-1 and CCL5, critical for macrophage
recruitment, and VEGF and other proangiogenic cytokines
such as IL-8 which recruit vascular cells [42]. Transcriptional
control of these factors is mediated by multiple transcription
factors, but speciﬁcally, it has been shown that two speciﬁc
factors, NF-κB and HIF-1, are critical for many of these
molecules. Several studies have demonstrated that PPARγ
activation can inhibit activation of NF-κBi nN S C L C[ 43,
44]. While eﬀects on HIF-1 have not been documented
in lung cancer cells, PPARγ has been shown to inhibit
HIF-1 in other systems [45]. These data indicate that
activation of PPARγ may disrupt communication between
cancer cells and the surrounding tumor microenvironment,
thus blocking progression and metastasis, distinct from
antiproliferative eﬀects on the tumor cells. In lung cancer,
where metastasis has often occurred at the time of diagnosis,
agents, which speciﬁcally target tumor-stromal interactions,
represent a novel therapeutic approach.
6. UPSTREAM ACTIVATION OF PPARγ
While TZDs have received most of the attention as PPARγ
activators, it is becoming apparent that activation of PPARγ
can occur as a consequence of activation of other signaling
pathways (see Figure 1). Phosphorylation by the ERK mem-
bers of the MAP kinase family has been shown to decrease4 PPAR Research
PPARγ activity, likely through altering the aﬃnity for ligand
binding [46]. Work in endothelial cells has demonstrated
that ﬂow-mediated activation of ERK5, a member of the
MAP kinase family, results in activation of PPARγ [47],
which may mediate anti-inﬂammatory eﬀects associated
with laminar ﬂow. In this case, the mechanism of activation
involves direct binding of ERK5 to the hinge region of
PPARγ. In lung cancer, our studies have focused on the role
oftheWntsignalingpathway.WhilecanonicalWntsignaling
has been implicated as promoting colon carcinogenesis,
the role of the Wnt pathway in nonsmall cell lung cancer
appears to be more complex. Our studies have demonstrated
that Wnt7a signaling through its receptor Fzd9 inhibits
transformedgro wthofNSCL Ccelllines[48].Furtherstudies
indicated that this pathway leads to increased PPARγ activity
through activation of ERK5, and that this increase in PPARγ
activity mediated the antitumorigenic eﬀects of Wnt7a/Fzd9
signaling [49].
A connection has also been made between prostacyclin
and activation of PPARγ. Prostaglandin I2 (PGI2, prosta-
cyclin), produced through the cyclooxygenase pathway via
prostacyclin synthase (PGIS), is a bioactive lipid with anti-
inﬂammatory, antiproliferative, and potent antimetastatic
properties [50, 51]. Our laboratory has shown that trans-
genic mice with selective pulmonary PGI2 synthase (PGIS)
overexpression exhibited signiﬁcantly reduced lung tumor
multiplicity and incidence in response to either chemical
carcinogens or exposure to tobacco smoke [52, 53], sug-
gesting that manipulation of the arachidonic acid pathway
downstreamfromCOXisatargetforlungcancerprevention.
IIoprost,along-lastingprostacyclinanalog,alsoinhibitslung
tumorigenesis in wild-type mice. PGI2 can signal through
a speciﬁc cell surface receptor, designated IP, which is a
member of the G-protein coupled receptor family, and
signals through increases in cAMP [54]. However, PGI2
has been shown to signal through activation of PPARs,
with reports of both PPARγ [55]a n dP P A R δ activation
[56, 57]. To deﬁne the downstream eﬀector of PGI2 in the
chemoprevention of lung cancer, studies were performed
in which mice overexpressing PGIS were crossed with mice
deﬁcient in IP (A. M. Meyer et al., unpublished observa-
tions). In a chemical carcinogenesis model, lack of IP did
not aﬀect protection against lung tumorigenesis mediated by
PGIS overexpression, suggesting IP-independent pathways.
Furtherstudyisrequiredtowhetherprostacyclincanactivate
PPARγ in vivo, and whether this eﬀect is mediated through
IP or represents a direct, IP-independent activation.
To test the role of PPARγ in chemoprevention of lung
cancer, we have developed transgenic mice overexpressing
PPARγ under the control of the surfactant protein C pro-
moter,whichtargetsexpressiontothedistallungepithelium.
In a chemical carcinogenesis model, these mice showed a
marked protection against developing lung tumors [44].
While the connection between prostacyclin analogs and
PPARγ activation needs to be more precisely deﬁned, from a
therapeuticstandpoint,theabilitytoactivatePPARγ through
non-TZD mechanisms represents an attractive strategy that
may avoid some of the deleterious eﬀects seen with TZD
administration.
7. MECHANISMS OF PPARγ ACTION IN
LUNG CANCER CELLS
In spite of intensive study examining the biological eﬀects of
PPARγ activationinlungcancer,muchlessisknowregarding
the direct targets of PPARγ (see Figure 2). As a member of
then uclearr ec ept orsuperfamily ,PP ARγ isaligand-activated
transcription factor. Thus, one assumes that there are direct
transcriptional targets, where PPARγ, in combination with
the RXR receptor, binds to regulatory elements and induced
transcription. These targets have been diﬃcult to identify
in cancer cells. In fact, most of the responses that have
been demonstrated involve suppression of target genes (e.g.,
cytokines). While PPARγ has been shown to upregulate E-
cadherin in NSCLC, there are no studies demonstrating
direct binding of PPARγ to the E-cadherin promoter. A
family of transcription factors have been identiﬁed which
act as suppressors of E-cadherin expression. Members of this
familyinclude Snail1, Snail2 (Slug),ZEB1,and Twist[58,59]
are potent inducers of EMT. Both Snail and Twist appear
to play critical roles in breast cancer metastasis [60, 61].
Overexpression of ZEB-1 has been implicated in mediating
EMT in NSCLC cells [62].
Several studies have reported increased expression of
the protein and lipid phosphatase PTEN in response to
PPARγ activation [63, 64]. Increased expression/activity of
PTEN would be anticipated to inhibit signaling through
PI-3 kinase/Akt, and downstream eﬀectors such as mTOR.
Decreased activation of Akt could lead to inhibition of NF-
κB signaling [65–67], although the molecular mechanisms
are not well deﬁned.
Elevated expression of cyclooxygenase-2 (COX-2) is
common in NSCLC, and mediates increased production of
PGE2 [68]. Activation of PPARγ has been shown in inhibit
COX-2 expression and decrease PGE2 production in NSCLC
[44,69].WhilethemechanismswherebyPGE2 contributesto
growthandprogressionofNSCLCarenotcompletelyunder-
stood, recent data in colon cancer have shown that PGE2
acting through its cell surface receptor can engage β-catenin
signaling, leading to proliferation [70]. Consistent with such
a model, TZDs also inhibit expression of the EP2 receptor,
which couples to β-catenin signaling [71]. Regulation of
PGE2 production by TZDs can also occur through PPARγ-
independent pathways. Both rosiglitazone and pioglitazone
can directly activate 15 hydroxyprostaglandin dehydroge-
nase, promoting breakdown of PGE2.
8. CONCLUSIONSAND FUTURE DIRECTIONS
Activation of PPARγ appears to inhibit lung tumorigenesis
at several diﬀerent stages. Animal studies indicate that
increased PPARγ may be chemopreventive against develop-
ing lung tumors, suggesting that it can block the early stages
of epithelial transformation. In established lung cancer, acti-
vation of PPARγ can inhibit proliferation, induce apoptosis,
and promote a less invasive phenotype through promoting
epithelialdiﬀerentiation,andperhapsblocking EMT.Finally,
through disruption of tumor-stromal communication via
inhibition of chemokine production, PPARγ can negativelyRaphael A. Nemenoﬀ et al. 5
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Figure 2: Eﬀector pathways for PPARγ in NSCLC.P P A R γ can increase either expression of enzymatic activity of PTEN. This results in
inhibition of Akt activation (pAkt), which may be involved in the growth inhibitory responses seen with PPARγ activation. Decreased Akt
activity also can lead to decreased activity of the transcription factor NF-κB. NF-κB is a critical transcription factor in the production of
proangiogenic and proinﬂammatory cytokines such as VEGF, IL-8. Decreased production of these factors would be expected to inhibit
recruitment of inﬂammatory cells such as macrophages, and block tumor angiogenesis. PPARγ-mediated suppression of members of the
Snail family of transcription factors, such as Snail, Zeb, or Twist, would lead to derepression of E-cadherin expression and promote the
epithelial phenotype, leading to decreased migration and invasiveness. PPARγ-mediated suppression of COX-2 expression in NSCLC has
been shown by several investigators. This would result in decreased PGE2 production, which will impact growth. TZDs can inhibit PGE2
production through a PPARγ-independent pathway involving induction of 15-hydroxyprostaglandin dehydrogenase (PGDH). Pathways
indicated in green are increased or activated by PPAR, while those in red represent pathways that are inhibited or repressed.
impact tumor progression and metastasis. These data make
PPARγ activators attractive agents for the treatment and
prevention of lung cancer.
However, a number of signiﬁcant issues remain to be
resolved. In many of the studies described in this article,
it is not clear if the biological responses are mediated
through “on-target” activation of PPARγ, or through other
“oﬀ-target” eﬀects. A strategy to address this issue is
the use of molecular approaches, either overexpressing or
silencing PPARγ in cancer cells to complement studies
with pharmacological agents. Genetic mouse models using
targetedknockoutsofPPARγ ineithercancercellsorstromal
compartments will also be informative. This strategy also
applies to deﬁning the mechanisms mediating the adverse
cardiovascular events reported in patients taking TZDs.
Deﬁning the molecular targets of TZDs mediating a speciﬁc
response will be critical in the further development of
second-generation PPARγ drugs. If adverse cardiac events
are mediated through “oﬀ-target” eﬀects, then a more
selective PPARγ activator would be therapeutically eﬀective,
withoutleadingtoadversecardiacevents.Alternatively,ifthe
antitumorigenic eﬀects of TZDs are mediated through “oﬀ-
target” eﬀectors, then identifying these pathways would lead
to novel therapeutic targets. Finally, the majority of studies
have focused on NSCLC. Studies deﬁning mechanisms of
activation and downstream targets in SCLC are needed
to determine if PPARγ represents a therapeutic target for
treating these forms of lung cancer.
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